The FDA has approved Flyrcado (flurpiridaz F 18) for evaluating myocardial ischemia and infarction in adults with known or suspected coronary artery disease (CAD). This cyclotron-produced radioactive diagnostic drug is used for positron emission tomography (PET) myocardial perfusion imaging (MPI) during rest or stress. Flyrcado is administered via intravenous injection, enhancing diagnostic capabilities for heart conditions.